Literature DB >> 10210232

MIRD Pamphlet No. 14 revised: A dynamic urinary bladder model for radiation dose calculations. Task Group of the MIRD Committee, Society of Nuclear Medicine.

S R Thomas1, M G Stabin, C T Chen, R C Samaratunga.   

Abstract

UNLABELLED: The constant-volume urinary bladder model in the standard MIRD Pamphlet No. 5 (Revised) phantom has recognized limitations. Various investigators have developed detailed models incorporating more physiologically realistic features, such as expanding bladder contents and residual volume, and variable urinary input rate, initial volume and first void time. We have reviewed these published models and have developed a new model for calculation of radiation absorbed dose to the urinary bladder wall incorporating these aspects.
METHODS: The model consists of a spherical source with variable volume to simulate the bladder contents and a wall represented by a spherical shell of constant volume. The wall thickness varies as the source expands or contracts. The model provides for variable urine entry rate (three different hydration states), initial bladder contents volume, residual volume and first void time. The voiding schedule includes an extended nighttime gap during which the urine entry rate is reduced to one-half the daytime rate.
RESULTS: Radiation-absorbed dose estimates have been calculated for the bladder wall surface (including photon and electron components) and at several depths in the wall (electron component) for 2-18F-fluoro-2-deoxy-D-glucose, 99mTc-diethylenetriaminepentaacetic acid (DTPA), 99mTc-HEDP, 99mTc-pertechnetate, 99mTc-red blood cells (RBCs), 99mTc-glucoheptonate, 99mTc-mercaptoacetyltriglicine chelator (MAG3), 99mTc-methylene diphosphonate (MDP), 99mTc-hexamethylpropylene amine oxime (HMPAO), 99mTc-human serum albumin (HSA), 99mTc-MIBI (rest and stress), 123I-/124I-/131I-OIH, 123I/131I-NaI, 125I-iothalamate, 111In-DTPA and 89Sr-SrCl.
CONCLUSION: The new model tends to give a higher radiation absorbed dose to the bladder wall surface than the previous models. Large initial bladder volumes and higher rates of urine flow into the bladder result in lower bladder wall dose. The optimal first voiding time is from 40 min to 3 hr postadministration, depending on radiopharmaceutical. The data as presented in tabular and graphic form for each compound provide guidance for establishing radiation absorbed dose reduction protocols.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10210232

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.

Authors:  Catherine L Gallagher; Bradley T Christian; James E Holden; Onofre T Dejesus; Robert J Nickles; Laura Buyan-Dent; Barbara B Bendlin; Sandra J Harding; Charles K Stone; Barb Mueller; Sterling C Johnson
Journal:  Mov Disord       Date:  2011-06-02       Impact factor: 10.338

2.  SNMMI Procedure Standard/EANM Practice Guideline for Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction 1.0.

Authors:  Andrew T Taylor; David C Brandon; Diego de Palma; M Donald Blaufox; Emmanuel Durand; Belkis Erbas; Sandra F Grant; Andrew J W Hilson; Anni Morsing
Journal:  Semin Nucl Med       Date:  2018-03-16       Impact factor: 4.446

3.  Biodistribution and Radiation Dosimetry of 124I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation.

Authors:  Catherine A Foss; Donika Plyku; Alvaro A Ordonez; Julian Sanchez-Bautista; Hailey B Rosenthal; Il Minn; Martin A Lodge; Martin G Pomper; George Sgouros; Sanjay K Jain
Journal:  J Nucl Med       Date:  2018-04-26       Impact factor: 10.057

4.  Comparative Dosimetry for 68Ga-DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors.

Authors:  Anders Josefsson; Robert F Hobbs; Sagar Ranka; Bryan C Schwarz; Donika Plyku; Jose Willegaignon de Amorim de Carvalho; Carlos Alberto Buchpiguel; Marcelo Tatit Sapienza; Wesley E Bolch; George Sgouros
Journal:  J Nucl Med       Date:  2018-02-09       Impact factor: 10.057

5.  Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.

Authors:  Cristian C Constantinescu; Cedric Tresse; MingQiang Zheng; Alexandra Gouasmat; Vincent M Carroll; Laetitia Mistico; David Alagille; Christine M Sandiego; Caroline Papin; Kenneth Marek; John P Seibyl; Gilles D Tamagnan; Olivier Barret
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

6.  Monte Carlo simulations of absorbed dose in a mouse phantom from 18-fluorine compounds.

Authors:  Richard Taschereau; Arion F Chatziioannou
Journal:  Med Phys       Date:  2007-03       Impact factor: 4.071

7.  Radiation exposure during transmission measurements: comparison between CT- and germanium-based techniques with a current PET scanner.

Authors:  Tung-Hsin Wu; Yung-Hui Huang; Jason J S Lee; Shih-Yuan Wang; Su-Cheng Wang; Cheng-Tau Su; Liang-Kung Chen; Tieh-Chi Chu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-08       Impact factor: 9.236

8.  GRPr Antagonist 68Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients.

Authors:  Ingrid L Bakker; Alida C Fröberg; Martijn B Busstra; J Fred Verzijlbergen; Mark Konijnenberg; Geert J L H van Leenders; Ivo G Schoots; Erik de Blois; Wytske M van Weerden; Simone U Dalm; Theodosia Maina; Berthold A Nock; Marion de Jong
Journal:  J Nucl Med       Date:  2021-03-31       Impact factor: 10.057

9.  Clinical translation of 18F-fluoropivalate - a PET tracer for imaging short-chain fatty acid metabolism: safety, biodistribution, and dosimetry in fed and fasted healthy volunteers.

Authors:  Suraiya R Dubash; Nicholas Keat; Kasia Kozlowski; Chris Barnes; Louis Allott; Diana Brickute; Sam Hill; Mickael Huiban; Tara D Barwick; Laura Kenny; Eric O Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-02       Impact factor: 9.236

10.  Safety, Biodistribution, and Radiation Dosimetry of 18F-rhPSMA-7.3 in Healthy Adult Volunteers.

Authors:  Tuula Tolvanen; Kari Kalliokoski; Simona Malaspina; Anna Kuisma; Salla Lahdenpohja; Ernst J Postema; Matthew P Miller; Mika Scheinin
Journal:  J Nucl Med       Date:  2020-10-16       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.